A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein (IMAGE)

Tsinghua University Press

A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein

Caption

Human neutralizing antibodies against RSV are isolated from the convalescent children. One potent monoclonal antibody RV11 potently neutralizes and prevent RSV infection, with higher efficacy compared to the widely used Palivizumab. RV11 binds to a conserved epitope across site IV/V of the fusion glycoprotein in its prefusion state.

Credit

George Fu Gao, Institute of Microbiology, Chinese Academy of Sciences

Usage Restrictions

News organizations may use or redistribute this image, with proper attribution, as part of news coverage of this paper only.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.